Global University Venturing rounds up some of the highlights from its London conference last month, which also featured the GUV Awards.

May issue editorial by Thierry Heles, editor, Global University Venturing

April issue editorial by Thierry Heles.

Versant's unusual build-to-buy model has resulted in Roche acquiring a target for MS based on UCSF research and the venture firm launching a new spinout, Pipeline Therapeutics.

The SoftBank-led series D round is indicative of a startup space where logistics, buying and transport are moving closer together.

James Mawson identifies issues raised at the World Incubation Summit and calls for input ahead of GUV's updated review of university venture funds to be published at GUV:Fusion in London in May.